ArticleNature2025
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- [Vaccination of immunocompromised individuals: Expert opinion - update 2026].Wiener klinische Wochenschrift · 2026Guideline
- COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors therapy in cancer patients: a meta-analysis of real-world studies.Frontiers in immunology · 2026Pooled it
- Precision Medicine and Artificial Intelligence in Next-Generation Cancer Surgery: A Comprehensive Analysis of Clinical Applications, Therapeutic Outcomes, and Implementation Strategies.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Repurposing licensed viral vaccines as anti-cancer therapeutics: Turning cold tumors hot.Human vaccines & immunotherapeutics · 2026Review
- Immune checkpoint inhibition enhances memory T-cell responses to CEF(T), SARS-CoV-2 spike proteins and ChAdOx1 nCoV-19.Human vaccines & immunotherapeutics · 2026Article
- SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Article
- Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.Lancet regional health. Americas · 2026Review
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
- COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.Nature medicine · 2026Article
- Reversing Macrophage Immunometabolic Dysfunction in Prolonged Infections Via a Glutaminolysis-Fueled Restoration-Based Hierarchically Selective Therapeutic System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer.Nature reviews. Clinical oncology · 2026Review
- Impact of the COVID-19 pandemic on cancer incidence, stage, mortality, and short-term survival in Ireland: a population-based analysis.ESMO real world data and digital oncology · 2026Article
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.Cancer research · 2026Article
- Impact of COVID-19 Vaccination on Patients with Non-Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitor Therapy: Real-World Evidence from Romania.Medicina (Kaunas, Lithuania) · 2026Article
- Advances in Therapeutic Melanoma Vaccines (2010-2025).Vaccines · 2026Review
- Single-Cell RNA-Sequencing Reveals Tumor Microenvironment Composition and Prior Therapy Modulate Response to Axl Inhibition.Cellular and molecular bioengineering · 2026Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors.
Adam J Grippin *Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. agrippin@mdanderson.org.ORCID 0000-0002-8076-4240
Christiano Marconi *Lillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Sage Copling *McGovern Medical School, Houston, TX, USA.
Nan Li *Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen BraunDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cole WoodyDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0000-3441-8446
Elliana YoungDepartment of Enterprise Data Engineering and Analytics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priti GuptaDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Min WangDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Annette WuDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seong Dong JeongDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dhruvkumar SoniLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Frances WeidertLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Chao XieLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Eden GoldenbergLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Andrew KimMcGovern Medical School, Houston, TX, USA.
Chong ZhaoLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Anna DeVriesLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Paul CastilloLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Rishabh LohrayDepartment of Dermatology, Baylor College of Medicine, Houston, TX, USA.
Michael K RooneyDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Benjamin R SchrankDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8138-4250
Yifan WangDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7387-0654
Yifan MaDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9371-4365
Enoch ChangDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ramez KouzyDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kyle DysonDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7972-3249
Jordan JafarniaMcGovern Medical School, Houston, TX, USA.ORCID 0000-0001-7195-9882
Nina NarimanMcGovern Medical School, Houston, TX, USA.ORCID 0009-0000-0069-6966
Gregory GladishDepartment of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jacob NewScripps Health, San Diego, CA, USA.ORCID 0000-0003-0707-9324
Ada ArguetaDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Diana AmayaDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nagheme ThomasLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Andria DotyLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Joe ChenDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nikhil CoplingUniversity of North Carolina, Chapel Hill, NC, USA.
Gabriel AlatrashDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0009-0000-8443-3150
Julie SimonDepartment of Surgical Oncology, Division Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alicia Bea DaviesDepartment of Surgical Oncology, Division Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William DennisDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Richard LiangDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeff LewisDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiong WeiDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Waree RinsurongkawongDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ara A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrew JohnsDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
D3CODE Team
Jack LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5469-9214
Ji-Hyun LeeDepartment of Biostatistics, The University of Florida, Gainesville, FL, USA.ORCID 0000-0001-6420-5150
Ryan SunDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1176-1561
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4658-055X
Hai TranDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jianjun ZhangDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7872-3477
Don L GibbonsDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-2362-3094
Jennifer WargoDepartment of Surgical Oncology, Division Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-3438-7576
Betty Y S KimDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6890-8355
John V HeymachDepartment of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9068-8942
Hector R Mendez-GomezLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Wen JiangDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9154-633X
Elias J SayourLillian S. Wells Department of Neurosurgery, Preston A. Wells, Jr. Center for Brain Tumor Therapy, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. elias.sayour@neurosurgery.ufl.edu.ORCID 0000-0002-5309-3197
Steven H LinDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. shlin@mdanderson.org.ORCID 0000-0003-4411-0634
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThe University of Texas MD Anderson Cancer Center SPORE in MelanomaP50CA221703 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAVIES, MICHAEL · 2019 to 2023
$10.3MCTSA K12 Program at The Scripps Research InstituteK12TR004410 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura Nicholson, Athena Philis-Tsimikas · 2023 to 2026
$3.9MOvercoming the blood-brain barrier with nanoparticle vaccines against gliomasR37CA251978 · NCI · UNIVERSITY OF FLORIDA · PI Elias Sayour · 2021 to 2026
$3.4MInterdisciplinary Translational Pre/Postdoctoral Program in Cancer NanotechnologyT32CA196561 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gang Bao, Konstantin V Sokolov · 2015 to 2026
$3.0MOvercoming metastatic spread of osteosarcoma with RNA loaded nanoparticlesR01CA266857 · NCI · UNIVERSITY OF FLORIDA · PI SAYOUR, ELIAS · 2022 to 2025
$2.9MFDA HHS R01 FD007268NCATS NIH HHS K12 TR004410NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA221703NCI NIH HHS R01 CA266857NCI NIH HHS R37 CA251978NCI NIH HHS T32 CA196561
Abstract
Immune checkpoint inhibitors (ICIs) extend survival in many patients with cancer but are ineffective in patients without pre-existing immunity
Indexed as
Cancer VaccinesCOVID-19 VaccinesImmune Checkpoint InhibitorsNeoplasmsSARS-CoV-2AnimalsAntigens, NeoplasmB7-H1 AntigenCD8-Positive T-LymphocytesCOVID-19FemaleHumansImmunity, InnateInterferon Type IMaleMiceAntigens, NeoplasmB7-H1 AntigenCancer VaccinesCD274 protein, humanCOVID-19 VaccinesImmune Checkpoint InhibitorsInterferon Type ImRNA VaccinesVaccines, Synthetic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.